Date   Headline
Apr 4, 2019 Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer
Mar 4, 2019 Adhera Therapeutics and Alyvant Enter into Digital Co-Promotion Agreement for Prestalia
Feb 6, 2019 Adhera Therapeutics' DyrctAxessTM Platform Helps 78% of Patients Adhere to PRESTALIA(R); Achieves Exceptionally High Level of Drug Adherence to an Antihypertensive Medication
Nov 20, 2018 Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update
Nov 20, 2018 Adhera Therapeutics Selects IQVIA’s OCE Technology Platform to Support Commercial Excellence
Oct 9, 2018 Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes
Oct 3, 2018 Marina Biotech Appoints Nancy R. Phelan to the Board of Directors
Sep 24, 2018 Marina Biotech Appoints Eric Teague as Chief Financial Officer
Aug 6, 2018 Marina Biotech Appoints Jay D. Schwartz to serve as Senior Vice President, Commercial Operations
Jun 29, 2018 Marina Biotech Appoints Uli Hacksell, Ph.D. and Robert C. Moscato to Board of Directors
Jun 20, 2018 Marina Biotech Appoints Robert Moscato to Chief Executive Officer
Feb 27, 2018 Marina Biotech Announces a New Publication on Prestalia®
Jan 16, 2018 Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio
Nov 27, 2017 Marina Biotech Appoints Isaac Blech to its Board of Directors
Oct 19, 2017 Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives
Oct 5, 2017 Marina Biotech Appoints Amit Shah as Chief Financial Officer
Aug 21, 2017 Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives
Aug 2, 2017 Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market
Jul 25, 2017 Marina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform
Jul 24, 2017 Marina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia®
Jul 19, 2017 Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics
Jul 5, 2017 Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman
Jun 26, 2017 Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)
Jun 6, 2017 Marina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy
May 30, 2017 Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases
Apr 27, 2017 Marina Biotech to Participate in Joseph Gunnar's Pioneers 2017 Conference on May 2
Apr 5, 2017 Marina Biotech Provides Business Update
Apr 3, 2017 Marina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer Tablet
Mar 29, 2017 Marina Biotech to Present Data on IT-102 and IT-103 at 2017 American Association for Cancer Research Annual Meeting
Mar 24, 2017 Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1
Mar 13, 2017 Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16
Mar 2, 2017 Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France
Mar 1, 2017 Marina Biotech to Participate in the 29th Annual ROTH Conference
Feb 21, 2017 Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer
Feb 14, 2017 Marina Biotech Announces Key Additions to its Executive Management Team
Feb 10, 2017 Marina Biotech Completes Share Issuance at a Valuation of $0.29 Per Share
Feb 7, 2017 Marina Biotech Announces a License Agreement to SMARTICLES
Jan 3, 2017 Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing
Dec 27, 2016 Marina Biotech to Update Its tkRNAi Clinical Program at Biotech Showcase
Dec 14, 2016 Philippe P. Calais to Join Marina Biotech's Board of Directors
Nov 25, 2016 Marina Biotech to Present at the 9th Annual LD Micro Main Event
Nov 16, 2016 Marina Biotech Announces Merger with IthenaPharma
Jun 2, 2016 Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French
May 17, 2016 Marina Biotech Provides First Quarter 2016 Financial Reports and Business Update
May 3, 2016 Marina Biotech to Acquire Late-Stage Program From Turing Pharmaceuticals
May 3, 2016 Marina Biotech Terminates Negotiations for Sale of Its Nucleic Acid Therapeutic Assets
Mar 31, 2016 Marina Biotech Provides 2015 Year-End Financials and Update
Mar 16, 2016 Marina Biotech Announces a License Agreement to Deliver a Genome Editing Technology
Mar 15, 2016 Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Feb 18, 2016 Marina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology
Feb 17, 2016 Marina Biotech to Explore Strategic Alternatives
Nov 19, 2015 Marina Biotech Reports Clinical and Preclinical Updates From SMARTICLES(R) Licensees Mirna Therapeutics and MiNA Therapeutics
Nov 17, 2015 Marina Biotech Receives Milestone Payment From SMARTICLES Licensee MiNA Therapeutics
Nov 16, 2015 Marina Biotech Announces Third Quarter 2015 Financial Results
Nov 3, 2015 Marina Biotech Reports That Licensee ProNAi Therapeutics Initiates 'Brighton' Phase II Trial of PNT2258 in Patients With Richter's Transformation
Sep 28, 2015 Marina Biotech and Hongene Biotechnology Announce License Agreement
Aug 13, 2015 Marina Biotech Announces Second Quarter 2015 Financial Results
Aug 6, 2015 Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Aug 5, 2015 Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis
Jun 10, 2015 Marina Biotech Expands European and Canadian Patent Protection of Its SMARTICLES Nucleic Acid Delivery Technology
May 14, 2015 Marina Biotech Announces First Quarter 2015 Financial Results
May 5, 2015 Marina Biotech Announces SMARTICLES(R)-Mediated Delivery of a Double-Stranded Oligonucleotide to Immune Cells
Apr 23, 2015 Marina Biotech Expands Global Patent Protection of Clinical Stage Nucleic Acid Delivery Technologies
Feb 25, 2015 Marina Biotech Provides 2014 Year-End Financials and Update
Dec 18, 2014 Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics
Dec 9, 2014 Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014
Nov 20, 2014 Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its First-in-Class microRNA-34 Mimic
Nov 18, 2014 Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
Nov 17, 2014 Marina Biotech Announces Third Quarter 2014 Financial Results
Sep 16, 2014 Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors
Sep 11, 2014 Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate
Sep 3, 2014 Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences
Aug 20, 2014 Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
Jun 12, 2014 Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
Jun 5, 2014 Marina Biotech Receives Decision to Grant Japanese Patent for Its SMARTICLES Nucleic Acid Delivery Technology
May 28, 2014 Marina Biotech to Present at the LD Micro Invitational 2014
May 14, 2014 Marina Biotech Provides Organizational Update
May 6, 2014 Marina Biotech Presents Clinical Data Demonstrating Delivery of Both Single and Double-Stranded Nucleic Acids to Tumors
Mar 11, 2014 Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases
Feb 27, 2014 Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid Delivery Technology
Feb 24, 2014 Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note
Jan 23, 2014 Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan
Jan 14, 2014 Marina Biotech Strengthens the Intellectual Property Estate for the Transkingdom RNA Interference Nucleic Acid Delivery Technology
Jan 9, 2014 Marina Biotech Strengthens the Intellectual Property Estate for SMARTICLES(R) Nucleic Acid Delivery Technology
Jan 3, 2014 Marina Biotech Announces Organizational Changes
Jan 2, 2014 Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics